What if these agents are psychiatric drugs that are masquerading as weight-loss drugs? Roger McIntyre More research is needed to confirm any potential connection between GLP-1 agonists and mental health, but several trials are ongoing
GLP-1 Receptor Agonists - Pharmacology Summary Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1 = Glucagon-like peptide 1
One placebo-controlled trial, called ATTAIN-MAINTAIN, followed adults who had previously completed the SURMOUNT-5 obesity trial, a randomized controlled study evaluating whether tirzepatide, the active ingredient in Zepbound, led to greater body weight reduction versus semaglutide in adults with obesity
Presented for research literature review only Kemper RA et al
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
GLP-1-based therapy for obesity